Proactive Investors - Run By Investors For Investors

Tissue Regenix adds arteries patent to portfolio

Tissue Regenix adds arteries patent to portfolio


Regenerative medical device specialist Tissue Regenix (LON:TRX) has added a patent for acellular arteries to its portfolio of replacment tissue and body products.

The new patent relates to the development of products for end stage renal disease such as Arteriovenous ('AV') dialysis grafts and coronary artery bypass grafts ('CABG').

Tissue said end-stage renal disease is growing at five times the rate of world population growth with an estimated 820,000 patients in the EU and US, 70% of whom receive dialysis annually.   

An estimated 60% of AV grafts fail within the first year, something Tissue Regenix said its product aims to address.

Tissue Regenix has developed a patented technology that involves taking human or animal tissue and “washing” it so that it can be used again to replace worn out or diseased body parts without the risk of rejection. 

Currently it is developing products to treat a range of vascular, cardiac, woundcare and orthopaedic problems. 

The patent is the also latest in its portfolio granted through its worldwide exclusive licence from the University of Leeds, it added.

Antony Odell, Tissue Regenix’s managing director, said: "This patent relating to 'Acellular Arteries' is an important addition to our global exclusive licence portfolio. 

"The AV dialysis graft product has the potential to address some of the issues associated with end-stage renal disease, a growing problem worldwide.  

“Growth in the disease is being driven by the globally ageing population, the higher life‐expectancy of treated ESRD patients and increasing access of a generally younger patient population to treatment in countries in which access to date has been limited."


View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.
Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use